StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)

Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –

Royalty Pharma cash

Cash and short-term investments held at the end of each period.

Royalty Pharma's cash was $836.99M at Jun 30, 2026. For fiscal 2025 it was $637.50M, down 35.4% from the year before. The highest annual figure on record is $1.92B in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$637.50M-35.4%
FY2024Dec 31, 2024$987.23M+99.3%
FY2023Dec 31, 2023$495.31M-71.1%
FY2022Dec 31, 2022$1.71B+6.5%
FY2021Dec 31, 2021$1.61B+49.0%
FY2020Dec 31, 2020$1.08B+338.1%
FY2019Dec 31, 2019$246.20M-87.2%
FY2018Dec 31, 2018$1.92B+39.3%
FY2017Dec 31, 2017$1.38B–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$836.99M+29.7%
Q1 FY2026Mar 31, 2026$608.30M-44.7%
Q4 FY2025Dec 31, 2025$637.50M-35.4%
Q3 FY2025Sep 30, 2025$955.04M-4.4%
Q2 FY2025Jun 30, 2025$645.11M-64.2%
Q1 FY2025Mar 31, 2025$1.10B+26.1%
Q4 FY2024Dec 31, 2024$987.23M+99.3%
Q3 FY2024Sep 30, 2024$998.55M+6.0%
Q2 FY2024Jun 30, 2024$1.80B-17.2%
Q1 FY2024Mar 31, 2024$872.00M-55.9%
Q4 FY2023Dec 31, 2023$495.31M-71.1%
Q3 FY2023Sep 30, 2023$941.75M-32.8%
Q2 FY2023Jun 30, 2023$2.18B-11.9%
Q1 FY2023Mar 31, 2023$1.98B+6.6%
Q4 FY2022Dec 31, 2022$1.71B+6.5%
Q3 FY2022Sep 30, 2022$1.40B-25.0%
Q2 FY2022Jun 30, 2022$2.47B+104.1%
Q1 FY2022Mar 31, 2022$1.86B+138.6%
Q4 FY2021Dec 31, 2021$1.61B+49.0%
Q3 FY2021Sep 30, 2021$1.87B+17.0%
Q2 FY2021Jun 30, 2021$1.21B-48.5%
Q1 FY2021Mar 31, 2021$778.07M+56.2%
Q4 FY2020Dec 31, 2020$1.08B+338.1%
Q3 FY2020Sep 30, 2020$1.60B+1271.5%
Q2 FY2020Jun 30, 2020$2.35B+296.1%
Q1 FY2020Mar 31, 2020$498.07M-74.1%
Q4 FY2019Dec 31, 2019$246.20M-82.2%
Q3 FY2019Sep 30, 2019$116.39M–
Q2 FY2019Jun 30, 2019$593.32M–
Q4 FY2018Dec 31, 2018$1.92B–
Q4 FY2017Dec 31, 2017$1.38B–

More Royalty Pharma figures

See a number that looks wrong?